Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DaVita (NYSE:DVA)
Q3 2019 Earnings Call
Nov 05, 2019, 5:00 p.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:


Operator

Good evening. My name is Debbie, and I will be your conference facilitator for today. At this time, I would like to welcome everyone to the DaVita third-quarter 2019 earnings call. [Operator instructions] Mr.

Jim Gustafson, you may begin your conference.

Jim Gustafson -- Vice President of Investor Relations

Thank you, Debbie, and welcome, everyone, to our third-quarter conference call. We appreciate your continued interest in our company. I'm Jim Gustafson, vice president of investor relations. And with me today are Javier Rodriguez, our CEO; Joel Ackerman, our CFO; Leanne Zumwalt, group vice president, and Jim Hilger, our chief accounting officer.

Please note that during this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our third-quarter earnings press release and our SEC filings, including our quarterly report on Form 10-Q for the second quarter of 2019, as updated by our quarterly report or Form 10-Q for the third quarter of 2019. Our forward-looking statements are based on the information currently available to us, and we do not intend and undertake no duty to update these statements.

Additionally, we'd like to remind you during this call, we will discuss some non-GAAP financial measures. Reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our press release submitted to the SEC and available on our website. I'll now turn the call over to our CEO, Javier Rodriguez.

Javier Rodriguez -- Chief Executive Officer

Thank you, Jim, and thank you for joining the call today. And as always, I will start with the clinical highlights to remind us, the clinical is at the heart of what we do here at DaVita. As we talked about at capital markets, over 50% of our patients begin dialysis treatments through the hospital setting, which is bad for the patients and expensive for the system. We're working hard to lower the number by helping the people to better manage their chronic kidney disease through two efforts: first, Kidney Smart, which is DaVita's community education program that provides free education on what the kidneys do, diet, medication, and treatment options, including home modalities and transplant.

I'm pleased to report that we have educated over 180,000 people through Kidney Smart, and we're making a difference. Based on our tracking, we know the Kidney Smart education individuals who transitioned to ESRD have better clinical outcomes, both during and after the transition. Additionally, 32% of Kidney Smart-educated individuals begin dialysis on a home modally, which is almost 5 times better than the general population. Our other key effort to improve chronic kidney care is our new nephrology-led entity, the Nephrology care lines, which will enable nephrologists to come together with DaVita to improve the care coordination for patients.

In this model, DaVita will create patient education and predictive analytics, while the physicians will contribute clinical expertise to help the patients slow kidney disease progression and start on home modality. These capabilities are important in both fee-for-service environment and as we continue to grow our value-based care arrangements. We're off to a good start. Two supporting points: first, over 500 phases have joined the alliance; and second, Dr.

Leslie Wang from the Cleveland Clinic has agreed to join DaVita to lead the way. Next, a few comments on our Q3 performance and results. Our adjusted operating income results continue to outperform our original estimates at the beginning of the year, and we have raised our 2019 adjusted operating income guidance for the second time this year. Calcimimetics has contributed to our OI performance, and we have delivered a great outcome.

In addition to resulting in positive financial results, our clinical and operational protocols have both improved health outcomes and driven savings to the healthcare system. While we expect at least one more quarter of positive economics, we continue to expect operating income from the calcimimetics to be near breakeven over the long-term. Regarding our financial goal of capital-efficient growth, our discipline on cost and capital continues with our goal of margin stability. We have delivered strong performance on labor productivity all year while actively managing our capital expenditures spend down.

These efforts have generated strong cash flow, a lot of which, we have deployed toward share buyback. Now, let me comment on some longer-term issues and developments since our last earnings call. First up, California. We're disappointed that Governor Newsom signed AB 290 into law despite clear evidence of the harm this union-backed legislation will cause for many of our most vulnerable patients in California.

Because of the law, the American Kidney fund has made it clear it will have to cease operation -- operating its patient assistance program in California as of January 2020. To remind you, this will leave nearly 4,000 low-income, primarily minority patients, without financial support that they rely upon to afford health insurance. We, along with other kidney care community, filed today a legal challenge to AB 290 in federal court in California because we believe violates the United States constitution. Also in California, we recently learned that the SCIU UHW has introduced another ballot initiative, which could be voted on in November 2020 election.

You may recall that in 2018, they sponsored a Proposition 8, which was rejected by the majority of California voters. The Union has until April to gather enough signatures to put the proposition on the ballot. We will oppose this new ballot initiative, which is simply another attempt to inflict harm on providers, physicians and patients, and we believe would add significant unnecessary cost to the system and the taxpayers. Now on to more constructive development.

Two weeks ago, CMMI released applications for -- applications for four voluntary integrated care models for CKD and ESRD. I won't get into the significant detail today, but let me make a few points. These models are nephrologists-centric. The models are complex, and we will work to educate the nephrologists to help them evaluate if these models make sense for their practice.

For us, the model appeared quite challenging in their current form and they will require significant investments that are unlikely to move the needle on the economics. In partnership with the community, we will continue to share the feedback with the government on ways to improve the model design and quality outcomes for patients. Finally, it's been a busy six months. And as many of you heard in capital markets, we laid our strategies for long-term success, including a new set of financial metrics and goals.

I'll be the first to acknowledge that we have more work to do to achieve our longer-term objective, and yet, as I interact with our caregivers, I'm even more confident that we're on a path to improve clinic care for our patients. In closing, we also announced today that Peter Grauer, the lead independent director on our board since 2003 and a member of our board since 1994 after he took Total Renal Care public, plans to retire from the board effective at our Annual meeting in 2020. After helping to lead the board through the chief executive transition in the sale of DMG, he believes it is now time to step down. We are forever grateful for his tremendous leadership and role in our organization.

Now on to Joel, who will provide additional details on the quarter.

Joel Ackerman -- Chief Financial Officer

Thank you, Javier. Let me start by providing our Q3 enterprise results for revenue adjusted operating margins and adjusted earnings per share from continuing operations attributable to DaVita. We generated $2.9 billion of revenue in the quarter, an increase of 2% over Q3 2018. As a reminder, in Q3 2018, DaVita Rx contributed approximately $100 million of revenue.

Our adjusted operating income was $462 million, resulting in adjusted operating margin of 15.9%, which includes approximately $74 million related to calcimimetics. Adjusted earnings per share from continuing operations attributable to DaVita was $1.53. Now, let me walk you through some of the underlying drivers, starting with the components of the U.S. dialysis and lab segment.

Non-acquired growth for the third quarter was 2.2%, effectively flat, compared to NAG in the prior two quarters. While we believe we are starting to see some progress in the leading indicators of NAG, it's too early to give any guidance on the timing or magnitude of potential improvement. Revenue per treatment was down sequentially by $0.56 driven by normal quarterly fluctuations in revenue. We continue to expect RPT for the full year to be in line with our guidance of up zero to 1% compared to 2018.

Combined patient care costs and dialysis and lab segment G&A were up approximately $1 per treatment quarter over quarter, driven primarily by higher compensation and benefits costs, offset by lower calcimimetic acquisition costs. Focusing on calcimimetics, we generated operating income from calcimimetics of approximately $74 million this quarter, as ASP remained relatively flat over Q2 while acquisition prices fell significantly. Revenue per treatment and cost per treatment for calcimimetics were $14.54 and $4.87, respectively. For full-year 2019, we now expect to generate approximately $220 million in profit from calcimimetics.

Now turning to international. For the quarter, adjusted operating income was approximately $1 million, including an FX gain of $3 million, and excluding an $84 million goodwill impairment to our German operations. For the full year, we continue to expect to generate positive adjusted operating income, excluding goodwill impairments and currency adjustments. Our effective tax rate on adjusted income attributable to DaVita from continuing operations for the quarter was 27.6%.

We continue to expect our adjusted tax rate attributable to DaVita for the full year to be between 28.5% and 29.5%. Now on to cash flow. In the third quarter, operating cash flow from continuing operations was $648 million and our newly defined free cash flow was $437 million. DSOs for the U.S.

dialysis and lab business declined sequentially by three days to 60 days in Q3 2019, in line with the improvement we forecasted early in 2019, and back to the level, it was at this time last year. Capex for the quarter was $173 million. We are revising full-year Capex guidance down by $60 million to $740 million to $780 million. Two primary factors are driving the change: first, we managed down our spend on de novo clinics; and second, we delayed spend on some self-development projects that will shift into 2020.

And we expect to see continued progress on reducing Capex in 2020. Since capital markets day we purchased an additional 8.9 million shares at an average price of $58.90 per share. As a result of these purchases, we've reduced our share count by approximately 36.9 million shares or 22% since the close of the DMG transaction. I'll conclude with some comments on our guidance range.

As Javier referenced, we're increasing our adjusted operating income guidance for the year to $1.74 billion to $1.77 billion, which includes our expectation of approximately $220 million of operating income from calcimimetics. We're also increasing our operating cash flow guidance from continuing operations for 2019 to $1.525 billion to $1.675 billion. For 2020, we're planning to give full guidance next quarter. In the interim, we are updating the 2020 adjusted EPS guidance we gave at our capital markets Day in September.

As a reminder, our guidance at capital markets Day was $5 to $5.50 per share and excluded any costs associated with ballot initiatives in 2020. At that time, we did not know if there would be any ballot initiatives introduced. Now that we know there is one being proposed, we've decided to incorporate the current estimated cost of opposing the initiative in our adjusted EPS range. Even after adding in this additional cost, we're increasing the range by $0.25 to $5.25 to $5.75 per share.

As a reminder, this range incorporates the estimated impact of AB 290. Operator, let's now open the line for questions.

Questions & Answers:


Operator

[Operator instructions] And our first question will come from Stephen Tanal with Goldman Sachs. Your line is now open.

Stephen Tanal -- Goldman Sachs -- Analyst

Good afternoon, guys. Thanks for the question. I guess, just the first thing to follow-up on, I guess, the new guidance for calcimimetics profit for the year implies about, I guess, $68 million or so in Q4 if we've been tracking this right? And I think, the reimbursement for the oral drug is flat sequentially from CMS. So, I just want to understand why this contribution would step down sequentially? Are costs going up? Or am I missing something else in that?

Joel Ackerman -- Chief Financial Officer

It's -- there's -- I'd say there's a bit of noise in the system. The reduction -- I wouldn't read anything material into the reduction.

Stephen Tanal -- Goldman Sachs -- Analyst

Got it. OK. And I guess, like kind of thinking through that a little bit further. So, the final rule came out of TDAPA, it looks like calcimimetics will go to ASP plus zero for next year.

It would seem like you guys are potentially buying better than the markets. So I guess, like shouldn't this leave room for a profit just given your scale? Or how should we think about that?

Joel Ackerman -- Chief Financial Officer

Yeah. So, I would say there certainly might be a little bit of profit. There could be a little bit of loss. There's some noise in the system associated with bad debt that we may not get reimbursed for and some other costs.

So, I don't think you'll see a big number in either side of zero, but I think zero is a reasonable starting point.

Stephen Tanal -- Goldman Sachs -- Analyst

Got it. OK. And then last for me, I guess, on the patient care cost side per treatment was down pretty significantly year on year. Wondered if you could kind of flesh out some of the bigger drivers there? Maybe touch on Epogen costs in that? And then, whether that's still a favorable kind of sequentially versus 2Q?

Joel Ackerman -- Chief Financial Officer

Yeah. So, year-over-year pharma costs did come down, and that is an important driver. Sequentially, it's not -- there's very little difference between Q2 and Q3 as it relates to EPO. Debbie, do we have another question?

Operator

Yes, the next question is from Kevin Fischbeck with Bank of America. Your line is now open.

Joel Ackerman -- Chief Financial Officer

Hey, Kevin.

Kevin Fischbeck -- Bank of America Merrill Lynch -- Analyst

Thanks. Hey. So, I just wanted to clarify the 2020 guidance change, it wasn't clear to me exactly why you were raising the EPS number, you're including AB -- but your -- is the rest -- what is the rest? Is it that there will be some calcimimetics benefit next into the beginning of next year? Or share repurchase? What was the --

Joel Ackerman -- Chief Financial Officer

Yeah. So, Kevin, I think the best way to think about the change in 2020 is a better share count number, to some extent, offset by the ballot initiative costs. As you would imagine, there are a bunch of moving pieces in there, and we're not ready to give 2020 guidance yet. Our budget isn't finished.

So, there are other moving pieces. But if you want to think about the dominant dynamics, it's share count driving it up, offset by ballot initiatives driving it down.

Kevin Fischbeck -- Bank of America Merrill Lynch -- Analyst

OK. And just to think about how we should be modeling calcimimetics into next year, does that kind of breakeven? Is that for the full year? Or did it kind of trend down toward breakeven, as the year goes on there may be a benefit at the beginning of the year, moving down to zero?

Joel Ackerman -- Chief Financial Officer

It could trend down a bit. It's hard to know. Because of the trajectory of ASP, it's hard to figure out in some of the cost issues. But I'd say -- it's fair to say, zero for the full year, trending down from a little bit positive at the beginning, potentially a little bit negative toward the end.

Kevin Fischbeck -- Bank of America Merrill Lynch -- Analyst

OK. And then, as far as the volume numbers that you talked about, I think you said that you're -- it's early. You're starting to see some leading indicators of NAG going positive. What are you exactly are you looking for when you talk about leading indicators? And what are you seeing that's giving you some optimism?

Joel Ackerman -- Chief Financial Officer

There's a couple of things that we look at, Kevin, but in essence, what we're doing is we're monitoring that the right shifts and the right capacity is going online in our centers and that our admissions execution are -- we're monitoring the demand into our centralized missions, and that's looking to stabilize right there.

Kevin Fischbeck -- Bank of America Merrill Lynch -- Analyst

OK. And then maybe last question, [Inaudible] versus us, it seemed like the big delta in the quarter was calcimimetics, and excluding that the quarter was pretty much in line. Is that how you were thinking about it internally? Or how did this quarter come in versus your internal expectations?

Joel Ackerman -- Chief Financial Officer

Kevin, I think that's a reasonably fair way to look at it. There is a little bit of cost relating to LTIP that is elevated as a result of calcimimetics. So, you can think about that in different ways. You could attribute it to calcimimetics.

You could say it's noise in the comp line, as we always have noise in the comp line. But I think yours is a reasonably good starting point.

Kevin Fischbeck -- Bank of America Merrill Lynch -- Analyst

All right. Great. Thanks.

Operator

The next question will come from Justin Lake with Wolfe Research. Your line is now open.

Joel Ackerman -- Chief Financial Officer

Hello, Justin.

Justin Lake -- Wolfe Research -- Analyst

Thanks. Hi, how are you doing? Good evening. So, I just wanted to go through a few things here. First, your share repurchase assumptions.

So, you ended the quarter, I think, with a little over $1.2 billion. You bought back $250 million, so call it, $1 billion-plus cash flow this quarter. I think you typically like to run around $500 million. So, should we think about kind of the dry powder that's left, $500 million kind of plus whatever free cash flow you generate going forward? Is that the reasonable way to think about it?

Joel Ackerman -- Chief Financial Officer

So, I start thinking about our share buyback philosophy, thinking about our leverage range and our comments about intrinsic value, and all that kind of stuff. If your question is narrow, how much excess cash is on the balance sheet right now, net of the buybacks that have happened since September 30? I think your math is pretty spot on.

Justin Lake -- Wolfe Research -- Analyst

OK. That's helpful. And then the ballot initiative, I appreciate you kind of putting that in the 2020 numbers. Is it reasonable to think of that spend that you've built in there in a similar ballpark to the incremental spend you had in 2018 to fight off that ballot initiative?

Joel Ackerman -- Chief Financial Officer

Yeah. So, it's -- I'll tell you, it's a tough number to predict from where we are right now. That said, I think that's a reasonable number to start with. As we've kind of played with it, we would say kind of a max of $0.50 a share -- $0.50 of EPS would be the maximum impact that we're looking at right now.

But again, it's still pretty early to try and put a definitive range around that.

Justin Lake -- Wolfe Research -- Analyst

OK. And so then, if we just do some simple math, if the business is doing what you expected it to do, and to your point, you took up the EPS by $0.25 plus offset, let's call it, $0.25 to $0.50 of the ballot initiative cost, you basically assume that the share count -- the share count is ending up, let's call it, 10% to 12% better than what you previously expected, just because you're buying the stock materially cheaper, is that a reasonable kind of bow to put on this package?

Joel Ackerman -- Chief Financial Officer

I'm -- is your question, Justin, what are our assumptions today relative to a capital -- to the assumptions we're using at capital markets day? Or are you asking where do we think we'll be relative to today's share count next year?

Justin Lake -- Wolfe Research -- Analyst

No, I guess, what I'm asking is more of the former, right? At the capital markets day, your share assumptions got you to $5 to $5.50. Now effectively, they're getting you -- if I exclude the ballot initiative, they're getting you more to like $5.50, $5.75 to $6, $6.25. So, it's just you're taking up the -- I'm just trying to make sure I understand the magnitude of the share repurchase improvement relative to what you thought is that entire movement, which is again, north of 10% of EPS ex-ballot?

Joel Ackerman -- Chief Financial Officer

Justin, let's come back to this question in a couple of minutes. There are some heads nodding yes and some heads nodding no. So, we'll do some quick math here, and I'll come back to you in a couple of minutes.

Justin Lake -- Wolfe Research -- Analyst

All right. I'll get back in the queue then. Thanks, guys.

Operator

The next question comes from Pito Chickering with Deutsche Bank. Your line is now open.

Pito Chickering -- Deutsche Bank -- Analyst

Hey, guys. Thanks for taking my questions. If you go over the patient care costs in the quarter? It sounds like calcimimetics moved about $4 sequentially. So, excluding that, it's still down 620 year over year.

EPO was part of that. Can you break out how much of that decline came from nursing costs?

Joel Ackerman -- Chief Financial Officer

So -- I'm sorry, you're asking year over year on treatment from -- Pito, I don't have that number. I don't think we've ever disclosed anything anywhere near that level of granularity.

Pito Chickering -- Deutsche Bank -- Analyst

So look, is it fair to think that if we look at the year-over-year decline in patient care costs, excluding sequentially the favorable impact from calcimimetics at $6.20, is it fair to think that half of that is labor and half of that is areas like drugs like EPO? Or is there any sort of detail you can give us or why that would keep on declining so well?

Joel Ackerman -- Chief Financial Officer

Yeah. So Pito, I'm thinking about year over year, so not in the quarter, specifically, and I think it -- year over year gives you a cleaner number takes out some of the noise. As we think about patient care costs, our expectations are -- will come inside the guidance range, which is, remember, up 0.5% to 1%, and if you think about how do we get there? It's comp pressure. So, maybe that's what you're asking about, and that comp pressure comes largely in the form of wage rate pressure.

And that's offset by the EPO decline. I mean, there are a bunch of other things going on in there, but at a very high level, I think that's a reasonable way of thinking about it. But year over year, the cost per treatment is up, not down.

Pito Chickering -- Deutsche Bank -- Analyst

OK, fair enough. The organic treatment growth looks to have stabilized this quarter. Is there a sense you can talk about sort of possible headwinds you face from facilities hitting max capacity in states like California?

Joel Ackerman -- Chief Financial Officer

So I mean, we've -- I guess, we've talked about this before. In terms of the pressure that can come in terms of admissions growth, if you're running labor too efficiently, and you can think about it as max capacity, you can think about it as ships being full and the pressure to not open a new ship because of the negative impact that can have on labor productivity. So that's a dynamic that we're keeping a careful eye on. I wouldn't necessarily attribute it to any specific market, but the dynamic you're calling out is certainly one that we're keeping a careful eye on.

Pito Chickering -- Deutsche Bank -- Analyst

Great. And then last question for me. As there's more and more focus on treating patients at home versus in the center, can you sort of break out what percent of your patients are treated at home? And if we're seeing nephrologist begin to sort of change their behavior to get more patients now?

Javier Rodriguez -- Chief Executive Officer

Peto, this is Javier. The mix is roughly 12% PD and a little below the 2% on HHD. So, we're a little below the 14 if you combine the two modalities. The PD is growing at a nice healthy trend, and it's similar to what it was before we had the shortage.

And so, there is clearly an interest in making sure that the patients go to the right modality, but we have seen this in years in the past.

Pito Chickering -- Deutsche Bank -- Analyst

Great. Thanks so much.

Joel Ackerman -- Chief Financial Officer

Thank you.

Operator

Our next question comes from Whit Mayo with UBS. Your line is now open.

Joel Ackerman -- Chief Financial Officer

Hey.

Whit Mayo -- UBS -- Analyst

Hey, afternoon. So in the final ESRD rule, admittedly, I haven't read the whole thing. But was there anything that surprised you with QIP, AKI, anything? I know there's this innovative transitional drug add-on change for supplies, equipment. Just wasn't sure if that means anything for you?

Joel Ackerman -- Chief Financial Officer

LeAnne, do you want to comment on that?

LeAnne Zumwalt -- Group Vice President

Sure. First, the final rule is very similar, almost exactly to the preliminary rule, and so, they had teed up that certain medical supplies which will be truly innovative, could get some partial incremental reimbursement. So that's positive, for sure, but it was not a surprise. Does that answer your question?

Whit Mayo -- UBS -- Analyst

I think so. Maybe it would be helpful to explain, elaborate a little bit more with maybe an example of how the TDAPA work for this new supply and equipment? I guess I don't fully understand how it works.

LeAnne Zumwalt -- Group Vice President

Well, I don't think they gave complete detail, but what I can tell you is that, in the final rule, they said the equipment or supply must represent an advancement that has substantially improved renal dialysis services. So, that's kind of their orientation. There is going to be a process to which these devices will be as introduced after 1/1/2020, and it will be -- the decisions will be made through the FDA Marketing Authorization. So, I'm not sure what exactly you're looking for, I'd be happy to answer specific questions or take it off-line with you if you want.

Whit Mayo -- UBS -- Analyst

No, that's really helpful. Thanks, LeAnne. My other question, I just wanted to kind of talk about California for a second, and let's assume that you and the industry, the AKF were unsuccessful getting perhaps an injunction filed, and we actually see the AKF pull out of the state altogether. What are the other options for patients at this point? I mean, presumably, you've thought some about this.

I'm just sort of curious, come January 1st, like what ultimately may happen?

Joel Ackerman -- Chief Financial Officer

Yeah, it's going to be very interesting to see how it plays out. And then, of course, there are different categories. In some instances, that patients will be able to get funding in some other way. And in some instances, they're going to lose their coverage.

And so, we're trying to do math around it, and that's why we try to be helpful with the range that we provided and we embedded in our guidance. But the reality is that we've never been in a situation like this, and that's why the range is a bit wide.

Whit Mayo -- UBS -- Analyst

I mean, is there another -- when I'm thinking about other ways to obtain premium support, the only thing that comes to mind is tax credits, premium support, and the exchange marketplaces. Is there any other obvious substitution for premium support?

Joel Ackerman -- Chief Financial Officer

Not that we are aware of. Of course, we are pursuing all options. Some might qualify for medical and other things, so that's why the math is a little tricky. And again, the range is a bit wide.

Whit Mayo -- UBS -- Analyst

OK. No, that's helpful. And maybe two real quick ones. Joel, I don't know if you commented on commercial mix, if not, can you -- can we get the actual ending share count on September 30th? I don't know if you gave that either?

Joel Ackerman -- Chief Financial Officer

Yeah. But we didn't comment on commercial mix, there's not a lot to talk about. Q3 tends to be seasonally a little bit weaker because of Medicare open enrollment, but nothing significant.

Whit Mayo -- UBS -- Analyst

Ending share count?

Joel Ackerman -- Chief Financial Officer

So, the ending share count at the end of Q3 was just under 134 million, 133.9 million. Remember, that excludes the shares we bought back right in the quarter ended.

Whit Mayo -- UBS -- Analyst

Right. Great. Helpful. Thanks, guys.

Joel Ackerman -- Chief Financial Officer

I'm sorry, before the next question, Justin, I want to get back to you. It's always hard to compare ranges, but roughly speaking, I think you can think of our share count forecast being down about 10% relative to what we talked about at capital markets day.

Operator

And our next question will come from Gary Taylor with J.P. Morgan. Your line is now open.

Joel Ackerman -- Chief Financial Officer

Hey, Gary.

Gary Taylor -- J.P. Morgan -- Analyst

Hey, good afternoon. Just a few quick ones. For the 2020 ballot initiatives, did I miss that? Did you size what you thought that would be?

Joel Ackerman -- Chief Financial Officer

Yeah, Gary, we -- I'd say, two ways to think about it. One is using what we spent in 2018 as a potential proxy, the second is we were thinking, if you want to think about it on an earnings per share basis, we would say $0.50 impact on 2020 would be at a kind of a max.

Gary Taylor -- J.P. Morgan -- Analyst

Gotcha. And will you call that out for us in the quarterlies like you did in 2018? What that spend is in the quarter?

Joel Ackerman -- Chief Financial Officer

I expect we will. I think we'll -- we're trying to develop a pattern of calling out things that are unusual, like calcimimetics and the ballot initiatives. So, the answer is yes. I do want to remind everyone on the call that the spend on the ballot initiatives is not tax-deductible.

So, as you're modeling the impact on EPS, keep that in mind.

Gary Taylor -- J.P. Morgan -- Analyst

Just another one. When I look at full-year from where we started the year in January, your OI guidance is up $130 million to $200 million. Am I right that calcimimetics started the year at an $80 million OI assumption that's now a $220 million? So, the low end of that is covered by the calcimimetics increase?

Joel Ackerman -- Chief Financial Officer

Yeah. So, Gary, I don't think we gave a specific calcimimetics number at the beginning of the year. If I were to think about a number for early year calcimimetics, I think your number is a bit high. So, if you're trying to say, of the OI increase from the beginning of the year, how much of that is the result of calcimimetics? And therefore, what's been the -- what's our thinking about core OI now relative to the beginning of the year? I think it is safe to say that the vast majority of the increase is the result of calcimimetics core OIs up a bit, but not a lot.

Gary Taylor -- J.P. Morgan -- Analyst

Thank you. Last question. I know last quarter, we were surprised by the magnitude of labor productivity you had in the quarter. And I know your thoughts at that time where that was going to reverse to some degree.

So, as I sit here and sort of adjust for the decline in the calcimimetics costs in the quarter, etc., I mean, it looks like labor productivity wasn't as good as you experienced in the 2Q, but still looks very attractive on a year-over-year basis. Is that the way you're looking at it? Is there anything else? Any other color on those 2Q productivity gains and how they carried into the third quarter?

Javier Rodriguez -- Chief Executive Officer

With you're directionally -- sorry, Gary, you're directionally correct on the math that you said. A couple of things to call out, as well is, as our volumes decrease, we did a great job of adjusting. And I think we've explained the interdependencies between sometimes having labor and volume and the correlation of managing both of those pieces. So, we did go up over 2Q, and we do, with what we're seeing, we expect it to go up even further in Q4 as we're seeing the hiring numbers, and the trending costs for the fourth quarter.

Gary Taylor -- J.P. Morgan -- Analyst

OK. Thank you.

Javier Rodriguez -- Chief Executive Officer

Thank you.

Operator

The next question will come from Justin Lake with Wolfe Research. Your line is now open.

Justin Lake -- Wolfe Research -- Analyst

Thanks. I appreciate you letting me in for a couple of follow-ups. You mentioned the impact of the benefit from -- or the impact of LTIP this year should reverse next year. Is there any kind of number you want to throw out for that that we should kind of keep in mind?

Joel Ackerman -- Chief Financial Officer

Not really. It's relatively small. And I think they're -- it's not something I would call out as a significant headwind or tailwind going from '19 to '20.

Justin Lake -- Wolfe Research -- Analyst

OK. And then, obviously, we're now looking out to 2020 and thinking about 2021. First, just for a second, it's just simple to say that 2020 earnings that you've got out there now are depressed by about $0.50 because of the ballot. There's no offsetting good guide there to think about such that 2021, there would be effectively a $0.50 tailwind as the ballot initiative costs go away just because there's no ballots that year? And earnings are automatically $0.50 higher before you kind of think about capital deployment of core growth? Is there any kind of offsets you want to throw out there before we kind of think about that?

Joel Ackerman -- Chief Financial Officer

No, I think the $0.50 is a pretty clean headwind into next year and tailwind into '21.

Justin Lake -- Wolfe Research -- Analyst

That's helpful. And then just a couple of follow-ups. I think Pito asked about home starts. Clearly, I think, yourselves and others are pushing to accelerate home, so I think the number you gave there of 12% and 2% was your current number, would it be helpful maybe to share with us the new starts, and how that might have changed over the last couple of years? Or even just the last three to six months as it seems to become a bigger push, have you seen any kind of meaningful change there?

Joel Ackerman -- Chief Financial Officer

The reality, Justin, is that we had a bit of a disruption with the shortage of supply. So, it's hard to connect. But it -- pre-supply shortage, we were running around the same rates that we are now, which is in the low-double-digits, so anywhere between 12 -- sorry, 10% and 13% on PD. The HHD has been more in the flattish range.

So, the people that fall out are roughly replaced with the newcomers. Did that answer your question?

Justin Lake -- Wolfe Research -- Analyst

OK. That really isn't -- the new starts really isn't any different, is your point?

Joel Ackerman -- Chief Financial Officer

Well, they're different than they were a couple of years ago because we had the shortage. And then, of course, you have to staff up, and you got to tell people that you're ready, and you got to get the market to be confident that you can supply it, etc. And so, we are actually quite energized by how quickly the market reacted and how much interest there is. And again, I think with what we said in capital markets, it's also not looking like there's going to be transformational, but rather, evolutionary change.

Justin Lake -- Wolfe Research -- Analyst

Got it. And then, Javier, you guys put in an 8-K yesterday that kind of talked about your new compensation agreement, and it looked pretty unique in that it looked like you're pulling forward about five years of stock comp into one. And so, I just wanted to know if there's -- I know in the -- there was a strike price number in that, I think, in the high-67s before you're in the money on those RSUs. But is there anything else in terms that we should know about in terms of vesting that? Do you have to hit certain hurdle rates? Is that in the proxy, I can go dig out? Number one, and maybe, you could just give us some color on kind of given this is fairly unique from what I've seen in my time, and I just love to kind of hear kind of how you thought about this and how the board thought about it? And I know you ran it by shareholders as well, so maybe just spend a minute on that? Thanks.

Joel Ackerman -- Chief Financial Officer

Justin, it's Joel. I'll take this. On the narrow question of vesting, it vest 50% at the end of the year three and 50% at the end of year four. There is no performance vesting.

I think the concept here is creating a premium price is effectively what's used to ensure that Javier gets significant value when the shareholders get significant value. And that's really what the board was trying to create here, it was an alignment of incentives between the new CEO and the long-term shareholders of that company. And I think, there was a lot of support as we went out to talk to shareholders. And I would add, this will be put to a vote by the shareholders.

So, all the shareholders would get the opportunity to approve this. So really, the guiding principle here was aligning incentives for the new CEO for the long-term shareholders. And I would -- one other point I'd highlight is that there is a five-year holding period here. So, this isn't about driving the stock price up toward a single or two separate vesting events.

Javier has to hold the stock that he gets here for five years.

Justin Lake -- Wolfe Research -- Analyst

Thanks for all the color there. I appreciate it.

Operator

The next question comes from Pito Chickering with Deutsche Bank. Your line is now open.

Pito Chickering -- Deutsche Bank -- Analyst

Hey, thanks. At this point, all my questions have been answered. So, thanks so much.

Joel Ackerman -- Chief Financial Officer

All right. Thanks, Pito.

Operator

The next question will come from John Ransom with Raymond James. Your line is now open.

Joel Ackerman -- Chief Financial Officer

Hi, John.

John Ransom -- Raymond James -- Analyst

Him, guys. Hey, let's pick a point in time, a couple of years ago, where all the payers were met at you about the exchanges, you had some tough negotiations. And let's say that was the idea where are you. I mean, this is a qualitative question, but where are you kind of long-term with some of your key payers.

And I know it's always going to be somewhat at the serous because of the structure of the industry, but what steps are you taking to maybe dial down some of that -- some of that contention?

Joel Ackerman -- Chief Financial Officer

Yeah. Thanks, John. In general, I think you've stated, we had some issues on understanding what happened with the exchanges in relation to our industry and the economics of the dialysis industry. I've gone down on a CO roadshow with several of the largest payers, and continue to reach out to many to make sure that, a, they understand the dynamics and the framework that we have and how unique it is; two, I want to make sure that they're clear that we are very into long-term sort of value arrangement, and that we are open to being creative in a new structure that we are not married to some kind of fee-for-service old structure, that we are confident that we are the best to be the primary care for our patients because of the amount of time they spend with us, and all the co-morbid conditions that we can impact.

And that we can structure something that is both good for the patient, good for the payers, and good for us. And so, that's why we're excited to build the capabilities of integrated care. That message is resonating, but as you know, it takes two to dance. And it's a complicated systems arrangements and math to make sure that you get holistic cost across the commercial population, etc., to establish benchmarks and trends so they can do good risk arrangement.

So we're up and running. I think the conversations will take years, so, you're not going to wake up one day and say, wow, there was a tectonic shift. I might be wrong on that. But it looks like it will be a slower transition, but the payers are reacting quite well to it.

John Ransom -- Raymond James -- Analyst

OK. And yeah, it's your fate in life to be between difficult pieces. So thinking of difficult people, physicians, one of the things we hear is this move to home. And you guys have said it too, is a bit of -- it is a culture and a physician training issue, and you have some markets where you have very little, you have some markets where it's 25%.

So again, qualitative question, where are you in your charm initiative with the doctors to get some of them maybe to think a little more about PD, as a first alternative versus maybe what some of them might be defaulting to the clinic?

Javier Rodriguez -- Chief Executive Officer

Yeah, our physicians are actually quite reasonable and what they want to do is make sure they do what's right for the patient. And they really worry about what's right for the patient and what's right for the system, and they're very independent in their nature, and then, their thinking. And so, what we have to do is make sure that we put the right science and the right specific and the right analytics, so they get trained and encourage the right patients to go home. And once we do that, the doctors are quite onboard to do whatever is right for the patient and the system.

So, we're working on that. And of course, we have thousands of them. So, it takes some time. And as you said, some are more bullish, and some would want to wait to see how it plays out.

John Ransom -- Raymond James -- Analyst

OK. That's it for me. Thank you.

Javier Rodriguez -- Chief Executive Officer

Thank you, John.

Operator

The next question comes from Matt Larew with William Blair. Your line is now open.

Javier Rodriguez -- Chief Executive Officer

Hi, Matt.

Matt Larew -- William Blair -- Analyst

Hey, good afternoon. Thanks for taking my question. Javier, I wanted to focus on your comments around some of the CMMI models, you'd mentioned that they would require significant investment upfront and that maybe, not quite like it moved the needle for you in the near-term. Are there things in particular that you're providing feedback to for CMS? And things you'd like to see change that would make them more compelling, both for you and the -- their nephrologist partners?

Javier Rodriguez -- Chief Executive Officer

We are -- the industry is actually very well aligned, including MEDPAC. So, there's a lot of comments out there that try to make sure that people understand how this work. If I were to use something to be useful for you, Matt, is, they're a little like -- their frameworks are a little like the ESCOs, and then, more complicated. And so, we now have experience on how surprising it is in, let's call it, difficult to understand how and what you're going to get paid because of benchmark changes and there's little visibility to it.

So, imagine adding all that risk, but now, you have a physician practice instead of a well-capitalized corporation. And so, physician practice would have to be out-of-pocket and not know exactly what its cash flows would be, and so, that's really an uncomfortable position for a small business. And so, we have a lot of more detail, but in general, I think that's a good, healthy way to think about it.

Matt Larew -- William Blair -- Analyst

OK. Thanks.

Javier Rodriguez -- Chief Executive Officer

Thank you.

Operator

We show no further questions in queue at this time.

Javier Rodriguez -- Chief Executive Officer

Well, I want to close out by thanking all of you. We will continue to work hard for you and for our patients, talk to you next quarter.

Operator

[Operator sign-off]

Duration: 52 minutes

Call participants:

Jim Gustafson -- Vice President of Investor Relations

Javier Rodriguez -- Chief Executive Officer

Joel Ackerman -- Chief Financial Officer

Stephen Tanal -- Goldman Sachs -- Analyst

Kevin Fischbeck -- Bank of America Merrill Lynch -- Analyst

Justin Lake -- Wolfe Research -- Analyst

Pito Chickering -- Deutsche Bank -- Analyst

Whit Mayo -- UBS -- Analyst

LeAnne Zumwalt -- Group Vice President

Gary Taylor -- J.P. Morgan -- Analyst

John Ransom -- Raymond James -- Analyst

Matt Larew -- William Blair -- Analyst

More DVA analysis

All earnings call transcripts